**US0231112063 - ADR - After market: 1.06 -0.04 (-3.64%)**

Taking everything into account, **AMRN** scores **2** out of 10 in our fundamental rating. **AMRN** was compared to 638 industry peers in the **Biotechnology** industry. **AMRN** has a medium profitability rating, but doesn't score so well on its financial health evaluation. **AMRN** has a expensive valuation and it also scores bad on growth

The profitability ratios for **AMRN** are negative, so there is not much use analyzing them.

The Piotroski-F score of **AMRN** is **1.00**. This is a very weak score and indicates problems in health and profitability for **AMRN**.

ROA (-10.27%) VS Industry: 88% outperformed.

-1,441.42

115.38

Profit Margin (-21.02%) VS Industry: 83% outperformed.

-1,173,705.71

8,610.80

With a price book ratio of **0.76**, **AMRN** is valued rather cheaply.

Compared to an average industry price book ratio of 1.59, **AMRN** is valued rather cheaply

The **Price/Earnings Ratio** is negative for **AMRN**. In the last year negative earnings were reported.

Also next year **AMRN** is expected to report negative earnings again, which makes the also the **Forward Price/Earnings** Ratio negative.

Price/Book (0.76) VS Industry: 72% outperformed.

162.47

0.08

Based on estimates for the next 5 years, **AMRN** will show a decrease in **Revenue**. The Revenue will decrease by **-8.02%** on average per year.

The **Earnings Per Share** is expected to decrease by **-55.26%** on average over the next 5 years. This is quite bad

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

Past | Future | ||||||
---|---|---|---|---|---|---|---|

5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |

EPS | N/A | N/A | -1900% | -1181.2% | -195.21% | -76.66% | -55.26% |

Revenue | 34.99% | 36.52% | -23.34% | -38.24% | -24.47% | -13.78% | -8.02% |

A Current Ratio of **1.99** indicates that **AMRN** should not have too much problems paying its short term obligations.

The Debt to Equity ratio of **AMRN** is in line with the industry averages.

Compared to an average industry Current Ratio of 6.52, **AMRN** is worse placed to pay its short term obligations than its industry peers. **87%** of its industry peers have a better Current Ratio.

When comparing the Quick Ratio of **AMRN** to the average industry Current Ratio of **6.48**, **AMRN** is less able to pay its short term obligations than its industry peers. **91%** of its industry peers have a better Quick Ratio.

Based on the Altman-Z score of **-0.90**, we must say that **AMRN** is in the distress zone and has some risk of bankruptcy.

The Piotroski-F score of **AMRN** is **1.00**. This is a very weak score and indicates problems in health and profitability for **AMRN**.

Debt/Equity (0) VS Industry: 43% outperformed.

18.24

0.00

Quick Ratio (1.36) VS Industry: 9% outperformed.

0.03

399.16

Current Ratio (1.99) VS Industry: 13% outperformed.

0.08

401.12

Altman-Z (-0.9) VS Industry: 45% outperformed.

-1,821.48

293.92

No dividends for **AMRN**!.

NASDAQ:AMRN (9/26/2022, 7:00:00 PM)**+0.01 (+0.92%) **

GICS Sector | Health Care | ||

GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||

GICS Industry | Biotechnology | ||

Earnings (Last) | 08-03 2022-08-03/bmo | Earnings (Next) | N/A N/A |

Ins Owners | 0.43% | Inst Owners | 33.83% |

Market Cap | 443.53M | Analysts | 52.31 |

PE | N/A | Fwd PE | N/A |

PEG (NY) | N/A | PEG (5Y) | N/A |

P/S | 0.93 | P/B | 0.76 |

EV/EBITDA | -2.74 |

Dividend Yield | N/A | Dividend Growth | N/A |

DP | N/A | Ex-Date | N/A |

EPS 1Y | -1900% | EPS 3Y | N/A |

EPS 5Y | N/A | EPS growth Q2Q | -650% |

EPS Next Y | -1181.2% | EPS Next 2Y | -195.21% |

EPS Next 3Y | -76.66% | EPS Next 5Y | -55.26% |

Revenue growth 1Y | -23.34% | Revenue growth 3Y | 36.52% |

Revenue growth 5Y | 34.99% | Revenue growth Q2Q | -38.87% |

Revenue Next Year | -38.24% | Revenue Next 2Y | -24.47% |

Revenue Next 3Y | -13.78% | Revenue Next 5Y | -8.02% |

Current Ratio | 1.99 | Quick Ratio | 1.36 |

Altman-Z | -0.9 | F-Score | 1 |

Debt/Equity | 0 |

ROA | -10.27% | ROE | N/A |

ROIC | N/A | ROICg | N/A |

PM | -21.02 | OM | -10.33 |

Asset Turnover | 0.49 |

*Find stocks with similar Fundamental rating on the USA*

*Find the competitors with the best fundamentals on the USA*

*Find the competitors with the best valuation on the USA*

*Find the competitors with the best dividend on the USA*